The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab
Pharmaceutics · 30.09.2023 · 15 (10) · 2408
DOI: 10.3390/pharmaceutics15102408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.09.2023. Verfasst von Marla C Dubinsky und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Medical Center, New York, NY 10029, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Prometheus laboratories.
Abstract (Originalsprache)
Infliximab (IFX) concentrations are a predictive factor (PF) of pharmacokinetic (PK) origin in the treatment of Crohn’s disease (CD). We evaluated Clearance, another PF of PK origin, either alone or in combination with concentrations. They were evaluated from two cohorts, the first designed to receive standard dosing (n = 37), and the second designed to proactively target therapeutic IFX concentrations (n = 108). Concentrations were measured using homogeneous mobility shift assay. Clearance was estimated using the nonlinear mixed effects methods with Bayesian priors. C-reactive protein-based clinical remission (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mount Sinai Medical Center, New York, NY 10029, USA.
- Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
- St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
- Prometheus Laboratories, San Diego, CA 92121, USA.
ORCID-Profile: John C Panetta
Förderung
- NIDDK NIH HHS
- Prometheus laboratories
Zitieren
APA
Dubinsky, M. C., Rabizadeh, S., Panetta, J. C., Spencer, E. A., Everts-van der Wind, A., & Dervieux, T. (2023). The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab. Pharmaceutics, 15(10), 2408. https://doi.org/10.3390/pharmaceutics15102408
Vancouver
Dubinsky MC, Rabizadeh S, Panetta JC, Spencer EA, Everts-van der Wind A, Dervieux T. The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab. Pharmaceutics. 2023;15(10):2408. doi:10.3390/pharmaceutics15102408
BibTeX
@article{Dubinsky2023,
author = {Dubinsky, Marla C and Rabizadeh, Shervin and Panetta, John C and Spencer, Elizabeth A and Everts-van der Wind, Annelie and Dervieux, Thierry},
title = {The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {10},
pages = {2408},
doi = {10.3390/pharmaceutics15102408}
}
EUVIMED